Systematic review: antibodies and anti‐<scp>TNF</scp>‐α levels in inflammatory bowel disease

Chaparro, María; Guerra, Iván; Linares, Pablo M.; Gisbert, Javier P.

doi:10.1111/j.1365-2036.2012.05057.x

Cited by 104 publications

(71 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is increasing evidence that TNF-α is key in the pathogenesis of IBD and may represent novel therapeutic targets (12). Studies indicate the TNF-α gene as an appropriate and functional candidate for IBD treatment (24,25). In the present study, the allele frequency of SNP-1031 T>C was greater in patients when compared with the control group, although the difference between the patients and control group was not significant.…”

Section: Discussioncontrasting

confidence: 33%

Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases

et al. 2017

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 33%

Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases

et al. 2017

View full text Add to dashboard Cite

“…This limits their utility in an individual patient, and measurement of anti-drug antibodies is therefore not currently part of standard clinical practice. Anti-infliximab antibodies are also associated with acute infusion reactions (PascualSalcedo et al, 2011;Atzeni et al, 2013) but not delayed hypersensitivity reactions (Chaparro et al, 2012). As is the case with efficacy, anti-infliximab antibodies are not universally associated with acute infusion reactions.…”

Section: A Anti-tumor Necrosis Factor Drugs In Rheumatoid Arthritismentioning

confidence: 99%

Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

et al. 2015

View full text Add to dashboard Cite

“…Nonetheless, inadequate anti-TNF drug concentrations and the presence of antidrug Abs (ADAbs) frequently have been implicated as predisposing factors for therapeutic failure and side effects (6). Furthermore, a recent study by Kneepkens et al (4) provided evidence for a significant association among disease activity, inflammation, and ETN concentrations in patients with AS at 24 wk of treatment.…”

mentioning

confidence: 95%

Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept

Detrez

Brouwers

Peeters

et al. 2016

The Journal of Immunology

View full text Add to dashboard Cite

The clinical response in ankylosing spondylitis (AS) patients treated with biologic agents can be influenced by pharmacokinetic variability among and within these patients. Therapeutic drug monitoring is seen as a valuable tool to improve patient care. The aim of this study was to generate a panel of mAbs toward etanercept (ETN) and to determine ETN and anti-ETN concentrations in AS patients. mAbs against ETN (MA-ETN) were generated using hybridoma technology. For quantification of ETN concentrations, a mAb-based TNF-coated ELISA and a mAb/mAb-based sandwich-type ELISA were developed. For evaluation of the anti-ETN Ab response, a bridging ELISA, as well as a functional cell-based assay, were constructed. Disease activity of the AS patients was measured with the AS Disease Activity Score (ASDAS). Active disease was defined as ASDAS ≥ 2.1. A total of 59 of 76 generated mAbs were ETN specific and were characterized further. Fifty-one mAbs revealed inhibitory properties in a cell-based assay. Analysis of serum concentrations of 21 ETN-treated AS patients with the TNF/MA-ETN68C5-HRP ELISA and the MA-ETN63C8/MA-ETN61C1-HRP ELISA revealed a good Pearson’s r (+0.974) but a poor intraclass correlation coefficient (+0.528) as the result of underestimation of the values in the former ELISA. At 24 wk, ETN concentrations were similar in patients with ASDAS < 2.1 and ≥ 2.1. Anti-ETN Abs were not detected in any of the patient samples tested. In conclusion, highly sensitive mAb-based immunoassays were developed for quantification of ETN and anti-ETN concentrations. The impact of these methods needs to be evaluated further in clinical practice.

show abstract

Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease

Abstract: SUMMARY BackgroundThe associations between clinical efficacy and infusion reactions with anti-TNF-a drug levels and the presence of antibodies against the drug have been described. However, the clinical utility of these tests in routine clinical practice remains unclear.

Cited by 104 publications

References 56 publications

Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases

Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases

Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept

Contact Info

Product

Resources

About